Company Description
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.
The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
| Country | Switzerland |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Ronen Twito |
Contact Details
Address: Hohstrasse 1 Kloten, 8302 Switzerland | |
| Phone | 41 44 512 21 50 |
| Website | newcelx.com |
Stock Details
| Ticker Symbol | NCEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001783036 |
| CUSIP Number | H5835A109 |
| ISIN Number | CH1442297896 |
Key Executives
| Name | Position |
|---|---|
| Ronen Twito CPA | Chief Executive Officer and Executive Chairman |
| Prof. Michel Revel M.D., Ph.D. | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board and Director |
| Omri Hagai | Chief Financial Officer |
| Alexander C. Zwyer M.B.A. | Chief Business Officer and Executive Director |
| Dr. Eric Konofal M.D., Ph.D. | Head of Doxa Program |
| Yossi Ben-Yossef | Honorary President and Strategic Consultant |
| Prof. Ariel Revel M.D. | Director of Medical Affairs |